Global Fibroblast Activation Protein Inhibitors Market, By Indications (Interstitial Cystitis, Crohn’s, Irritable Bowel, Chronic Prostatitis, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Fibroblast Activation Protein Inhibitors Market Analysis and Size
The global fibroblast activation protein inhibitors market is expected to witness significant growth during the forecast period. The growth of fibroblast activation protein inhibitors market is boosted by the increasing prevalence of cancer and upsurge in focuses on the fibroblast activation protein inhibitors. The market for fibroblast activation protein inhibitors is majorly hindered by limited revenue opportunities with delayed in approvals. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global fibroblast activation protein inhibitors market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Fibroblast activation protein is a cell-surface serine protease which are presented on numerous receptors and play a crucial role in the tumor growth. Fibroblast activation protein inhibitors are the novel approach for the treatment of various type of cancer. Cancer cells are often very sensitive to growth factors. Development of cancer growth impeders such as fibroblast activation protein (FAP) inhibitors can provide encouraging results in cancer management.
Fibroblast Activation Protein Inhibitors Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indications (Interstitial Cystitis, Crohn’s, Irritable Bowel, Chronic Prostatitis, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Prestige Consumer Healthcare Inc. (U.S.), PsiOxus Therapeutics (U.K.), Molecular Partners. (Switzerland)
|
|
Market Opportunities
|
|
Global Fibroblast Activation Protein Inhibitors Market Dynamics
Drivers
- Increased Clinical Research
There are many clinical activities that is happening globally by major market players which are boosting the growth of the market. For instance, one such inhibitor is Val-boroPro which is a single-agent inhibitor of fibroblast activation protein (FAP) enzymatic activity. Several clinical trials have been performed to assess the efficacy of Val-boroPro as fibroblast activation protein (FAP) inhibitor in targeting many cancers such as colorectal, pancreatic, lung, leukemia and melanoma. Thus, it boosts the market growth.
- Increased Prevalence of Cancer
As per the reports of the National Cancer Institute, approximately 1,685,210 new cases of cancer was detected in 2016 in the U.S alone. The most common types of cancer are breast cancer, colon and rectum cancer, prostate cancer, lung and bronchus cancer, bladder cancer, melanoma, kidney and renal pelvis cancer, leukemia, and pancreatic cancer. Thus, all these factors boost the growth of the market.
Opportunities
- Technological Development
Several technological developments in the field are constantly improving for the patients' better improvement. Major market players primarily focus on upgrading the drugs, which works as an opportunity for the market to grow. In addition to this, improving treatment, better equipment for disease detection, and hospital facilities are expected to boost the market demand. Thus, all these factors enhance the market expansion.
- Increasing Demand for Retail Pharmacies
The increasing demand of the renal drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Side Effects of Renal Drugs
The side effects associated with these inhibitors could curb the growth of the global fibroblast activation protein inhibitors market over a forecast period. Effects such as vomiting, nausea, pain, and several others, can hamper the market growth.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global fibroblast activation protein inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global fibroblast activation protein inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Fibroblast Activation Protein Inhibitors Market
COVID-19 left a major impact on the global fibroblast activation protein inhibitors market and even in the post pandemic situation, the market is expected to grow. Canceris the predominant disease that is independemt of its occurrence in the pandemic, Thus, the growth of these inhibitors market is expected to grow high during the pandemic and even post that.
Global Fibroblast Activation Protein Inhibitors Market Scope
The global fibroblast activation protein inhibitors market is segmented on the basis of indication, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Interstitial Cystitis
- Crohn’s
- Irritable Bowel
- Chronic Prostatitis
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Fibroblast Activation Protein Inhibitors Market Regional Analysis/Insights
The global fibroblast activation protein inhibitors market is analysed and market size insights and trends are provided by indication, distribution channel and end-user as referenced above.
The major countries covered in the global fibroblast activation protein inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a highest growth for global fibroblast activation protein inhibitors market throughout the forecasted period due rapidly improving health care infrastructure in the region.
North America dominates the market due to the high prevalence of cancer and increases focuses on the research and development activity by key players.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Fibroblast Activation Protein Inhibitors Market Share Analysis
The global fibroblast activation protein inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global fibroblast activation protein inhibitors market.
Key players operating in the global fibroblast activation protein inhibitors market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Prestige Consumer Healthcare Inc. (U.S.)
- PsiOxus Therapeutics (U.K.)
- Molecular Partners. (Switzerland)
SKU-